Tamtam Try Tamtam free
The Joint Chiropractic logo

The Joint Chiropractic account plan

Chiropractic care accessibility and improvement

At a glance

The Joint Corp. franchises The Joint Chiropractic, a cash-based US chiropractic chain with 930 clinics and $532.4 million of 2025 system-wide sales.

The Joint Corp. (Nasdaq: JYNT), headquartered in Scottsdale, Arizona, franchises The Joint Chiropractic clinics: retail-center chiropractic offices that need no appointment and use a private-pay, non-insurance, cash-based model aimed at non-acute care. It calls itself the largest chiropractic franchisor in the United States, with 960 clinics in 43 states at December 31, 2025 and 930 clinics at September 30, 2026 (915 franchised, 15 company-owned or managed). In 2025, system-wide sales were $532.4 million across 14.4 million patient visits, GAAP revenue from continuing operations rose 5.2% to $54.9 million and net income was $2.9 million. The company had approximately 202 full-time and 128 part-time employees at December 31, 2025, and more than 2,500 licensed chiropractic doctors work in the network. Under its "Joint 2.0" strategy it has sold nearly all company-owned clinics to become a capital-light, pure-play franchisor.

Business units

Strategic priorities

Complete the pure-play franchisor model (Joint 2.0)
Refranchising of all company-owned or managed clinics is substantially complete, with 15 left at September 30, 2026. The target model is G&A at 40%-42% of revenue, gross margin 83%-85% and Adjusted EBITDA margin 19%-21% (12% in 2025).
Improve comp sales in 2027
Comp sales were -4.2% in Q1, -2.8% in Q2 and -1.9% in Q3 2026; the CEO calls improving them the single priority for 2027, through new patient acquisition, conversion, retention and win-back of lapsed patients.
Grow new patients and active members
Marketing pivoted from wellness to pain relief and from local to national media from November 2025, with SEO work for AI-driven search; flexible AlignOne and AlignTwo membership plans aim to raise conversion and retention.
Buy back regional developer territories
Five territories with 189 franchised clinics, including Texas, were reacquired in 2026, worth approximately $3.0 million of annual RD royalty savings, about one-third offset by internal costs; the company will keep evaluating further buybacks.
Return to clinic growth
After closing underperforming clinics in 2026 (year-end count about 50 clinics lower than 2025), management expects clinic growth to resume in 2027, citing potential for more than 1,800 clinics in the U.S. and 150+ potential clinics in the reacquired territories.
Joint 3.0: new channels and markets
From 2027 the next phase is to add new channels, B2B, underpenetrated US markets and first international markets, with positioning on longevity, nutrition, orthotics and wearables data.

Latest results

In Q3 2026 (quarter ended September 30, 2026), revenue from continuing operations rose 1.3% to $13.6 million while system-wide sales fell 3.1% to $123.3 million and comp sales decreased 1.9% (after -2.8% in Q2 2026). Net income from continuing operations rose to $1.5 million (vs $0.3 million) and Adjusted EBITDA from continuing operations to $2.3 million (vs $1.4 million), but discontinued operations lost $1.6 million, leaving a consolidated net loss of $0.1 million. G&A fell to 51% of revenue (55% a year earlier). Over nine months, revenue rose 9.6% to $43.6 million. The company cut its 2026 guidance to system-wide sales of $508-$512 million (from $519-$552 million) and comp sales of -3.5% to -2.5%, citing "continued macroeconomic pressures on consumer spending", while keeping consolidated Adjusted EBITDA at $12.5-$13.5 million.

Investments and deals

Refranchising of corporate clinics
June 2025: 31 Arizona and New Mexico clinics sold to Joint Ventures, LLC for $8.3 million; December 2025: 22 Southeast clinics for approximately $1.5 million; April 20, 2026: 45 Southern California clinics to Elite Chiro Group for $2.3 million; June 28, 2026: four Northern California clinics to Vigeo, LLC for $400 thousand.
Texas regional developer buyback
On October 1, 2026 the company reacquired the Texas regional development rights (141 franchised clinics) for $8.0 million in cash plus up to $2.0 million tied to gross sales over two years.
AI-powered lead management platform
A new lead management platform supported by 6 AI agents launches in January 2027 to follow up on leads, book appointments and answer frequently asked questions; it should begin contributing to comps during 2027.
Share repurchases
$11.3 million of buybacks in 2025 under a $17.0 million program and $5.6 million in the first nine months of 2026; the program was exhausted at September 30, 2026 and the board authorized $5.0 million more on November 3, 2026.
Marketing technology and point of sale
Growth projects held to a 25% IRR hurdle include reworking and bringing in-house the MarTech stack and a consolidated point-of-sale interface for wellness coordinators; the mobile app adds wait times, in-app registration and patient recognition features.

Challenges and risks

Fewer new patients and lower spend
New patients fell to 797,100 in 2025 from 957,000; in Q3 2026 pressure on consumer spending led to fewer new patients and lower average patient spend per month, and flexible plans dilute spend by about $2 per patient per month.
Consumer sensitivity to the economy
Maintenance chiropractic is a discretionary expense; patients' household income is mostly $60,000-$110,000, so the 2026 guidance includes no price increase, and management cites inflation, gas prices and elevated interest rates.
Chiropractor shortage and labor costs
The 10-K names a nationwide shortage of chiropractors and labor-cost inflation, including minimum wage increases from January 1, 2026, as the main inflationary factor.
Shrinking network and slower franchise sales
Only one franchise license was sold in Q3 2026 (13 a year earlier), licenses sold but not yet developed fell to 47 from 86, and 37 franchised clinics closed in nine months.
Regulation and franchise risk
State rules on the corporate practice of chiropractic, joint-employer rules, dependence on independent franchisees and regional developers, and data privacy and cybersecurity are named risks.

What leadership says

“Our third quarter results show that the actions we have taken to strengthen patient engagement and reshape our operating model are beginning to work together.”

Sanjiv Razdan, President and CEO · Q3 2026 earnings call, November 5, 2026

“We are single mindedly focused on improving comp sales.”

Sanjiv Razdan, President and CEO · Q3 2026 earnings call, on the priority for 2027

“a highly efficient, capital-light pure-play franchisor with more consumer touch points and with strong free cash flow generation.”

Sanjiv Razdan, President and CEO · Q4 2025 earnings call, March 12, 2026, describing the end state of Joint 2.0

“new patient flow has been the weakest for us”

Scott Bowman, CFO · Q4 2025 earnings call, March 12, 2026

Where a supplier can help

Patient acquisition and AI search visibility
Tied to the new-patient challenge and the marketing pivot: suppliers of local and national media, SEO for AI-driven search and lead conversion tools can support the push to grow new patients and comp sales in 2027.
Retention, membership and app engagement
Tied to the comp sales priority: win-back campaigns, automated messaging, loyalty and app features help keep members longer, which the company says costs less than acquiring new patients.
Franchise development and site selection
Tied to the return to clinic growth: franchise recruitment, site selection and pre-opening marketing services fit the plan to resume openings in 2027 and develop the 150+ potential clinics in reacquired territories.
Chiropractor recruiting and workforce tools
Tied to the chiropractor shortage and labor-cost challenge: recruiting, scheduling and labor-efficiency tools for the network address the main inflationary factor management names.
Retail products and longevity offerings
Tied to Joint 3.0: the company is piloting orthotics and nutritional supplements and considering wearables data, opening room for product and technology partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like The Joint Chiropractic?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about The Joint Chiropractic

What does The Joint Corp. do?

It franchises The Joint Chiropractic, a chain of US chiropractic clinics in retail centers that need no appointment and accept cash or cards rather than insurance. It had 930 clinics at September 30, 2026, almost all franchised.

What is The Joint Corp.'s revenue?

GAAP revenue from continuing operations was $54.9 million in 2025, up 5.2%, on system-wide sales of $532.4 million. Nine-month 2026 revenue rose 9.6% to $43.6 million.

How many employees does The Joint Corp. have?

Approximately 202 full-time and 128 part-time employees at December 31, 2025; more than 2,500 licensed chiropractic doctors work across the clinic network.

What is The Joint Corp.'s strategy?

Under Joint 2.0 it has become a capital-light, pure-play franchisor by selling its company-owned clinics and buying back regional developer territories. Its 2027 priority is improving comp sales, followed by Joint 3.0 expansion into new channels, B2B and new markets.

Who leads The Joint Corp.?

Sanjiv Razdan has been President and CEO since October 2024, with CFO Scott J. Bowman since June 2025.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)